A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Detection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles
Tekijät: Verhassel, Alejandra; Kimani, Martha; Gidwani, Kamlesh; Sandholm, Jouko; Gawlitza, Kornelia; Rurack, Knut; Härkönen, Pirkko
Kustantaja: Taylor and Francis Ltd.
Julkaisuvuosi: 2024
Journal: Nanomedicine
Tietokannassa oleva lehden nimi: Nanomedicine
Vuosikerta: 19
Numero: 29
Aloitussivu: 2463
Lopetussivu: 2478
ISSN: 1743-5889
eISSN: 1748-6963
DOI: https://doi.org/10.1080/17435889.2024.2405454
Verkko-osoite: https://doi.org/10.1080/17435889.2024.2405454
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/458628849
Aim: Fluorescence detection of breast and prostate cancer cells expressing Tn-antigen, a tumor marker, with Vicia villosa lectin (VVL)-labeled nanoparticles.
Materials & methods: Breast and prostate cancer cells engineered to express high levels of Tn-antigen and non-engineered controls were incubated with VVL-labeled or unlabeled red dye-doped silica-coated polystyrene nanoparticles. The binding to cells was studied with flow cytometry, confocal microscopy, and electron microscopy.
Results: Flow cytometry showed that the binding of VVL-labeled nanoparticles was significantly higher to Tn-antigen-expressing cancer cells than controls. Confocal microscopy demonstrated that particles bound to the cell surface. According to the correlative light and electron microscopy the particles bound mostly as aggregates.
Conclusion: VVL-labeled nanoparticles could provide a new tool for the detection of Tn-antigen-expressing breast and prostate cancer cells.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
The study was funded as part of the European Network ‘GlycoImaging’ by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Action grant agreement No. 721297. Working grants were received from the University of Turku Graduate School (Drug Research Doctoral Programme), Ida Montinin Säätiö (The Ida Montin Foundation), K. Albin Johansson Foundation, Paulo Foundation and Lounais-Suomen Syöpäyhdistys (The Cancer Society of Southwestern Finland).